European Pharmaceutical Contract Manufacturing Market to Reach $108.1 Billion by 2035
European pharmaceutical contract manufacturing market is driven by the increasing outsourcing of drug development and manufacturing activities by pharmaceutical and biotechnology companies, aiming to reduce operational costs and improve production efficiency. The growing demand for complex biologics, personalized medicine, and advanced drug formulations is further accelerating the adoption of contract manufacturing services across Europe. Additionally, stringent regulatory compliance requirements and the need for high-quality manufacturing standards are encouraging companies to partner with specialized contract development and manufacturing organizations (CDMOs) to ensure scalability, reliability, and faster time-to-market.
Browse the full report description of “European Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report, By Manufacturing Process Type (Sterile Manufacturing, and Non-Sterile Manufacturing), By Product Type (OTC, API, Finished Dosage Formulation, and Others), By Route of Administration (Oral, Inhaled, Parenteral, and Others), By Service (R&D, Manufacturing, and Non-Clinical), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/european-pharmaceutical-contract-manufacturing-market
Sandoz expands European biosimilar manufacturing (2025)
Sandoz Group AG completed the acquisition of Just-Evotec Biologics EU SAS (Toulouse site) in 2025, significantly strengthening its biosimilars manufacturing and development capabilities in Europe. The acquisition enhances Sandoz’s internal biologics production capacity and integrates advanced continuous manufacturing technologies, improving efficiency and scalability in biologics production. This move also expands the company’s European manufacturing footprint, particularly by reinforcing operations across Slovenia and France, thereby supporting a more integrated and resilient biosimilars supply network in the region.
NextPharma divests logistics to focus pure CDMO model (2025)
In 2025, NextPharma divested its logistics business as part of a strategic shift toward becoming a pure-play Contract Development and Manufacturing Organization (CDMO). This restructuring allows the company to concentrate entirely on pharmaceutical manufacturing services across key dosage forms, including solid, semi-solid, sterile, and non-sterile products. The decision strengthens NextPharma’s specialization within Europe’s CDMO landscape by streamlining operations and focusing on core manufacturing capabilities, aligning with growing demand for outsourced pharmaceutical production.
Siegfried expands Swiss CDMO operations (2025)
Siegfried, a Switzerland-based CDMO, expanded its European manufacturing operations in 2025 through increased investments in both active pharmaceutical ingredient (API) and finished drug product manufacturing sites. The expansion particularly strengthens its high-potency API production capabilities, driven by rising demand from European pharmaceutical clients. This capacity enhancement supports more robust and compliant supply chains across regulated European markets, reinforcing Siegfried’s position in high-value, specialized pharmaceutical manufacturing services.
About OMR Global
OMR Global is a market intelligence and strategic consulting firm specializing in growth advisory, competitive intelligence, and AI-enabled business research across global B2B industries.
The company supports enterprises, investors, and technology providers with actionable insights for market entry, investment analysis, procurement strategy, commercialization, and business expansion. OMR Global combines industry expertise, primary research, analytics, and digital intelligence tools to help organizations navigate evolving market landscapes and identify growth opportunities.
OMR Digital Offerings
- Pulse Intelligence Platform – AI-powered market intelligence suite designed to deliver analyst-grade insights faster and more efficiently. Built on 12+ years of research expertise and enhanced with AI-driven analytics, Pulse helps organizations transform large volumes of market and company data into actionable intelligence within hours instead of weeks. Trusted by Fortune 500 enterprises, global investment banks, strategy consultancies, and PE & VC firms, Pulse supports strategic decision-making across investment evaluation, competitive benchmarking, AI readiness, and market positioning.
Other Offerings
- Lead Generation – Verified B2B prospect data, ICP targeting, and intent-based sales intelligence
- RFx Support – End-to-end RFP, RFI, and RFQ support with vendor benchmarking and evaluation frameworks
OMR Global delivers data-driven intelligence solutions designed to support strategic decision-making, operational efficiency, and long-term business growth.
To find out more, visit www.omrglobal.com
Contact:
Mr. Anurag Tiwari
305-308, Commerce House, Janjeerwala Square,
Indore, Madhya Pradesh 452001
India
+91-780-304-0404